Biogen Idec arthritis model gets personal

Using a patient dataset and some high-horsepower computing, researchers at Biogen Idec ($BIIB) and analytics company GNS Healthcare have built a rheumatoid arthritis disease model that lets them run patient-specific virtual clinical trials. This personalized-medicine stepping stone yields dynamic disease models of individualized patient outcomes, they say in PLoS Computational Biology.

The model generates predictions of the RA-sufferer's response to drugs, and the response to inhibiting drug targets and disease pathways. That's a first, says Colin Hill, CEO at GNS.

The collaborators used a patient dataset comprising genotyping, whole-blood gene expression profiles and such clinical measures as tender joints, swollen joints and C-reactive protein. They fed the data into GNS's supercomputer-driven platform, REFS (reverse-engineering and forward-simulation). REFS built the model.

- see the GNS release

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.